Dinoges-EV
Generic Name
Dienogest
Manufacturer
ACI Limited
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| dinoges ev 2 mg tablet | ৳ 1,680.00 | N/A |
Description
Overview of the medicine
Dinoges-EV 2 mg tablet contains Dienogest, a synthetic progestogen, used primarily for the treatment of endometriosis. It works by reducing the production of estrogen and suppressing the growth of endometrial tissue.
Uses & Indications
Dosage
Adults
2 mg dienogest daily without interruption, preferably at the same time each day, with or without food.
Elderly
Not applicable for post-menopausal women. No specific dosage adjustment required for elderly pre-menopausal women.
Renal_impairment
No specific dosage adjustment required for mild to moderate renal impairment. Data for severe renal impairment is limited.
How to Take
The tablet should be taken orally, once daily, at approximately the same time each day, with some liquid if necessary. It can be taken with or without food.
Mechanism of Action
Dienogest is a selective progestogen that binds to progesterone receptors with high affinity. It exerts its action by inducing decidualization of endometrial tissue, followed by atrophy of endometriotic lesions. It also has moderate antiandrogenic properties.
Pharmacokinetics
Onset
Clinical effects typically seen after several weeks of continuous treatment.
Excretion
Excreted primarily via urine (approximately 60%) and feces (approximately 40%) as metabolites.
Half life
Terminal half-life is approximately 9-10 hours.
Absorption
Rapidly absorbed after oral administration. Peak plasma concentrations are reached within 1.5 hours. Bioavailability is approximately 91%.
Metabolism
Extensively metabolized by the cytochrome P450 3A4 (CYP3A4) system, primarily via hydroxylation.
Side Effects
Contraindications
- Active venous thromboembolic disorder
- History of arterial or cardiovascular disease (e.g., myocardial infarction, cerebrovascular accident)
- Diabetes mellitus with vascular involvement
- Severe hepatic disease (current or history)
- Hepatic tumors (current or history, benign or malignant)
- Known or suspected sex hormone-dependent malignant tumours
- Undiagnosed vaginal bleeding
- Hypersensitivity to the active substance or to any of the excipients
Drug Interactions
CYP3A4 inhibitors (e.g., Ketoconazole, Erythromycin, Grapefruit juice)
May increase plasma concentrations of dienogest, potentially increasing side effects.
CYP3A4 inducers (e.g., Phenytoin, Rifampicin, Carbamazepine, St. John's Wort)
May decrease plasma concentrations of dienogest, reducing its therapeutic effect.
Storage
Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.
Overdose
No reports of serious harmful effects from overdose. Symptoms may include nausea, vomiting, and mild vaginal bleeding. Treatment is symptomatic.
Pregnancy & Lactation
Contraindicated during pregnancy. Not recommended during breastfeeding as dienogest and its metabolites are excreted in breast milk.
Side Effects
Contraindications
- Active venous thromboembolic disorder
- History of arterial or cardiovascular disease (e.g., myocardial infarction, cerebrovascular accident)
- Diabetes mellitus with vascular involvement
- Severe hepatic disease (current or history)
- Hepatic tumors (current or history, benign or malignant)
- Known or suspected sex hormone-dependent malignant tumours
- Undiagnosed vaginal bleeding
- Hypersensitivity to the active substance or to any of the excipients
Drug Interactions
CYP3A4 inhibitors (e.g., Ketoconazole, Erythromycin, Grapefruit juice)
May increase plasma concentrations of dienogest, potentially increasing side effects.
CYP3A4 inducers (e.g., Phenytoin, Rifampicin, Carbamazepine, St. John's Wort)
May decrease plasma concentrations of dienogest, reducing its therapeutic effect.
Storage
Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.
Overdose
No reports of serious harmful effects from overdose. Symptoms may include nausea, vomiting, and mild vaginal bleeding. Treatment is symptomatic.
Pregnancy & Lactation
Contraindicated during pregnancy. Not recommended during breastfeeding as dienogest and its metabolites are excreted in breast milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months
Availability
Pharmacies, Hospitals
Approval Status
Approved by major regulatory bodies
Patent Status
Generic available
Clinical Trials
Dienogest has undergone numerous clinical trials demonstrating its efficacy and safety in the treatment of endometriosis. Key trials include studies on pain reduction and lesion size decrease.
Lab Monitoring
- Regular gynecological examinations
- Blood pressure monitoring
- Monitoring for signs of thromboembolism
- Liver function tests if clinically indicated
Doctor Notes
- Advise patients about potential irregular bleeding patterns, especially during the initial months of treatment.
- Monitor bone mineral density in adolescent patients receiving long-term treatment.
- Assess patient history for thromboembolic risks before prescribing.
Patient Guidelines
- Take the tablet at the same time every day.
- Do not stop treatment without consulting your doctor.
- Inform your doctor if you experience any unusual bleeding or severe side effects.
- This medicine does not provide contraception, use non-hormonal contraception if needed.
Missed Dose Advice
If a dose is missed, it should be taken as soon as remembered, but only one tablet should be taken per day. Do not take a double dose to make up for a forgotten tablet.
Driving Precautions
No known adverse effects on the ability to drive or operate machinery.
Lifestyle Advice
- Maintain a healthy diet and regular exercise.
- Avoid smoking, as it increases the risk of thromboembolic events.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.